No Data
Leap and SWTCH Energy Launch New Virtual Power Plant Solutions for Multi-Tenant EV Charging Infrastructure
New partnership will scale innovative grid flexibility solutions to underserved multifamily property marketSAN FRANCISCO & TORONTO--(BUSINESS WIRE)--#EVcharging--Leap, the leading virtual power plant
Buy Rating Affirmed for Leap Therapeutics on Strong Trial Prospects and Solid Financials
Leap Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Leap Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : Maintaining the Leap Therapeutics (LPTX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $7.00 to $5.50.
HC Wainwright & Co. : Maintaining the Leap Therapeutics (LPTX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $7.00 to $5.50.
HC Wainwright & Co. Maintains Buy on Leap Therapeutics, Lowers Price Target to $5.5
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Leap Therapeutics (NASDAQ:LPTX) with a Buy and lowers the price target from $7 to $5.5.
Leap Therapeutics Inc (LPTX) Q1 2024 Earnings: Financial Resilience Amidst Clinical Progress